9 stories mentioning HKG:1672Updated 15d ago
Every FINWIRES story that references HKG:1672, newest first.
Ascletis Pharma (HKG:1672) commenced a phase 1 study for the ASC36 oral tablets in the U.S. for the treatment of obesity.The trial will study the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral amylin receptor peptide agonist in 86 participants with obesity, according to a Tuesday bourse disclosure.
Ascletis Pharma (HKG:1672) said it has been included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective Sept. 7.The inclusion allows mainland Chinese investors to trade the biotech company's Hong Kong-listed shares through the Stock Connect platform, according to a Monday Hong Kong bourse filing.Shares of the drugmaker rose over 2% in recent trade.
Ascletis Pharma (HKG:1672) said the first participant has been dosed in a global Phase III clinical program for ASC30, an oral drug being developed for long-term weight management and diabetes.The program comprises two late-stage trials involving about 4,600 participants across the U.S., Europe and Canada to assess the drug's effectiveness, safety and tolerability, according to a Sunday Hong Kong bourse filing.Shares of the company plunged over 5% in Monday's trade.
Ascletis Pharma (HKG:1672) initiated two phase I studies in the U.S. for ASC36 and ASC36_35FDC for the treatment of obesity.The move comes following investigational new drug clearance by the U.S. Food and Drug Administration (FDA), according to a Monday Hong Kong bourse filing.
Ascletis Pharma (HKG:1672) obtained phase III trial clearance for obesity drug ASC30 from the U.S. Food and Drug Administration (FDA), according to a Monday Hong Kong bourse filing.The company expects to announce topline data from the phase III program in the third quarter of 2028, with a U.S. FDA New Drug Application (NDA) filing anticipated by the end of that year.A European Medicines Agency (EMA) Marketing Authorization Application (MAA) filing is also expected in early 2029.
Ascletis Pharma's (HKG:1672) ASC37 demonstrated superior weight loss to tirzepatide in a diet-induced obese mouse model, according to a Monday Hong Kong bourse filing.The company will submit an investigational new drug application of both ASC37 once-monthly subcutaneous and oral formulations in the third quarter.Biologics license applications for the formulation will be submitted to the U.S. Food and Drug Administration after phase III completion.
Ascletis Pharma (HKG:1672) plans to repurchase up to HK$300 million of its shares on the open market under a general mandate approved by shareholders.The shares may be canceled, sold, transferred or held as treasury, as deemed appropriate by the board, according to a Tuesday Hong Kong bourse filing.
Ascletis Pharma (HKG:1672) obtained investigational new drug clearance from the U.S. Food and Drug Administration (FDA) for the phase I study of ASC3, according to a Tuesday Hong Kong bourse filing.The drug is being tested for the treatment of obesity.
Ascletis Pharma (HKG:1672) said it completed patient enrollment in the phase 2 study of its oral drug ASC30 in the U.S., according to a Hong Kong bourse filing Monday.The firm will study the drug as a treatment for type 2 diabetes over a 13-week period. Topline data from the investigation is expected in the third quarter of 2026, according to Ascletis.ASC30 is also being developed as a treatment for obesity.
